BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xuan JW, Song RL, Xu GX, Lu WQ, Lu YJ, Liu Z. Modeling the cost-effectiveness of ilaprazole versus omeprazole for the treatment of newly diagnosed duodenal ulcer patients in China. J Med Econ 2016;19:1056-60. [PMID: 27223846 DOI: 10.1080/13696998.2016.1194277] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Ou F, Zhou Y, Lei J, Zeng S, Wu F, Zhang N, Yu L. Development of a UHPLC-MS/MS method for the quantification of ilaprazole enantiomers in rat plasma and its pharmacokinetic application. J Pharm Anal 2020;10:617-23. [PMID: 33425456 DOI: 10.1016/j.jpha.2019.09.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Pu J, Wang F, Tang W, Zhu M. Biotransformation of Ilaprazole in Human Liver Microsomes and Human: Role of CYP3A4 in Ilaprazole Clearance and Drug-Drug Interaction. Drug Metab Dispos 2018;46:1453-61. [PMID: 30002078 DOI: 10.1124/dmd.118.081570] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
3 Zhang G, Guo K, Wang P, Shan Y, Ma C. Identification of the New In Vivo Metabolites of Ilaprazole in Rat Plasma after Oral Administration by LC-MS: In Silico Prediction of the H+/K+-ATPase Inhibitor. Molecules 2021;26:459. [PMID: 33467211 DOI: 10.3390/molecules26020459] [Reference Citation Analysis]
4 Zhang J, Ge L, Hill M, Liang Y, Xie J, Cui D, Li X, Zheng W, He R. Standard-Dose Proton Pump Inhibitors in the Initial Non-eradication Treatment of Duodenal Ulcer: Systematic Review, Network Meta-Analysis, and Cost-Effectiveness Analysis. Front Pharmacol 2018;9:1512. [PMID: 30666204 DOI: 10.3389/fphar.2018.01512] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
5 Hillman L, Yadlapati R, Thuluvath AJ, Berendsen MA, Pandolfino JE. A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease. Dis Esophagus 2017;30:1-15. [PMID: 28859358 DOI: 10.1093/dote/dox055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]